Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability‐High End‐Stage Cancers and Poor Performance Status Related to High Disease Burden

BACKGROUND: Few real‐world series on the efficacy and safety of anti‐programmed cell death protein‐1(PD‐1)/programmed death ligand‐1(PD‐L1)–based therapy are available in molecularly unselected patients with poor performance status (PS) and specific types of advanced cancers, because such population...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncologist
المؤلفون الرئيسيون: Pietrantonio, Filippo, Loupakis, Fotios, Randon, Giovanni, Raimondi, Alessandra, Salati, Massimiliano, Trapani, Dario, Pagani, Filippo, Depetris, Ilaria, Maddalena, Giulia, Morano, Federica, Corallo, Salvatore, Prisciandaro, Michele, Corti, Francesca, Guarini, Vincenzo, Bocconi, Alessandro, Marra, Antonio, Belli, Carmen, Spallanzani, Andrea, Fassan, Matteo, Lonardi, Sara, Curigliano, Giuseppe, Fucà, Giovanni, Di Bartolomeo, Maria, de Braud, Filippo
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley & Sons, Inc. 2020
الموضوعات:
Immuno‐Oncology
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485362/
https://ncbi.nlm.nih.gov/pubmed/32369650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0014
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة